| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CCN1; CCNA |
| Entrez GeneID | 890 |
| clone | 6B4D11 |
| WB Predicted band size | 48.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CCNA2 (AA: 105-233) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CCNA2抗体的模拟参考文献示例(仅供参考，实际文献请通过学术数据库查询)：
---
1. **"Cyclin A2 Expression in Colorectal Cancer: Correlation with Clinical Outcomes"**
*Authors: Zhang L, Wang Y, Chen H*
**摘要**：研究通过免疫组化(使用CCNA2特异性抗体)分析结直肠癌组织中Cyclin A2的表达水平，发现其高表达与肿瘤进展和患者生存率降低显著相关。
2. **"Development and Validation of a High-Affinity Anti-CCNA2 Antibody for Cell Cycle Studies"**
*Authors: Tanaka K, Sato R, Yamamoto T*
**摘要**：报道一种新型CCNA2单克隆抗体的开发，验证其在流式细胞术和Western blot中的应用，证实其对细胞周期S/G2/M期检测的特异性。
3. **"CCNA2 as a Potential Therapeutic Target in Hepatocellular Carcinoma"**
*Authors: Gupta S, Patel M, Kumar D*
**摘要**：利用CCNA2抗体研究肝癌细胞中Cyclin A2的功能，发现其沉默可抑制肿瘤增殖，提示其作为治疗靶点的潜力。
4. **"Cyclin A2 Antibody-Based Detection of Replication Stress in Cancer Cells"**
*Authors: Müller J, Fischer A, Braun S*
**摘要**：通过CCNA2抗体结合免疫荧光技术，揭示癌细胞在DNA复制应激下Cyclin A2的异常定位，为抗癌药物筛选提供新方法。
---
**提示**：以上为模拟示例，实际文献建议通过PubMed、Google Scholar等平台以关键词“CCNA2 antibody”“Cyclin A2 biomarker”等检索。
**Background of CCNA2 Antibody**
CCNA2 (Cyclin A2) is a key regulatory protein involved in cell cycle progression, primarily governing the transition from S phase to G2/M phase. It forms complexes with cyclin-dependent kinases (CDKs), such as CDK1 and CDK2. to drive DNA replication and mitotic entry. Dysregulation of CCNA2 expression is implicated in various cancers, where its overexpression often correlates with uncontrolled proliferation, genomic instability, and poor clinical outcomes.
The CCNA2 antibody is a vital tool for detecting and quantifying Cyclin A2 in research. It enables the study of cell cycle dynamics, cancer mechanisms, and therapeutic targets. In laboratory settings, this antibody is used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to analyze CCNA2 expression patterns in tissues or cultured cells. Additionally, it aids in exploring how CCNA2 interacts with CDKs or checkpoint proteins under stress or drug treatment.
Studies utilizing CCNA2 antibodies have revealed its dual role: while essential for normal cell division, its aberrant expression can trigger tumorigenesis. For example, elevated CCNA2 levels are observed in hepatocellular carcinoma, breast cancer, and gliomas, making it a potential biomarker or therapeutic target. Furthermore, research on CCNA2 inhibitors highlights its relevance in precision oncology. Overall, the CCNA2 antibody serves as a critical reagent for advancing our understanding of cell cycle biology and its implications in disease.
×
